tbuckley/cabot-search huggingface dataset:
SP0007 IS ULTRASOUND A GOOD TOOL TO EVALUATE CPPD?
Authors: Georgios Filippou
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> CPPD is an arthropathy with high prevalence among the elderly and a multitude of clinical manifestations that can easily bring to misdiagnosis and therapeutic errors. The possibility to assess different aspects of the disease with only one tool can be of great help for clinicians. Ultrasound (US) can help to address both the diagnosis and the inflammatory assessment of the disease. In the last years a lot of research has been carried out regarding the applications of US in CPPD. The special OMERACT US sub-task force that is working in CPPD has produced new definitions for identification of CPPD by US and has tested their reliability demonstrating that US can be used reliably at the knees and wrists for assessing CPPD[1,2]. Further, US has been tested also for assessment of inflammatory and structural changes in osteoarthritis demonstrating to be reliable also for this purpose[3]. During the lecture the potential of US in diagnosis and follow-up of patients with CPPD will be presented. Further, a deeper insight into possible pathogenetic mechanisms, based on observations made at US imaging, will be discussed. <h3>References:</h3> [1] Filippou G., Scirè C.A., Damjanov N., et al. Definition and reliability assessment of elementary ultrasonographic findings in calcium pyrophosphate deposition disease: A study by the OMERACT calcium pyrophosphate deposition disease ultrasound subtask force. J Rheumatol 2017;44:1744–9. doi:10.3899/jrheum.161057 [2] Filippou G, Scirè CA, Adinolfi A, et al. Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force. Ann Rheum Dis 2018;:annrheumdis-2017-212542. doi:10.1136/annrheumdis-2017-212542 [3] Bruyn GA, Naredo E, Damjanov N, et al. An OMERACT reliability exercise of inflammatory and structural abnormalities in patients with knee osteoarthritis using ultrasound assessment. Ann Rheum Dis Published Online First: 22 April 2015. doi:10.1136/annrheumdis-2014-206774 <h3>Disclosure of Interests:</h3> Georgios Filippou Speakers bureau: Laborest, Abbvie, BMS, Sanofi
Sustainable Discovery and Development of Antibiotics — Is a Nonprofit Approach the Future?
Authors: Travis B. Nielsen, Eric P. Brass, David N. Gilbert, John G. Bartlett, Brad Spellberg
Journal: New England Journal of Medicine (2019)

Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed drugs that improve patient outcomes and permit more effective control over the postapproval use of antibiotics to prolong their effectiveness.
AB0603 SCOTLAND’S FIRST FAST TRACK TEMPORAL ARTERY ULTRASOUND REFERRAL PATHWAY FOR SUSPECTED GIANT CELL ARTERITIS
Authors: John McLaren, Jane Gibson, Sarah Hailwood
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Giant cell arteritis (GCA) is associated with loss of vision (LOV). Rapid referral for specialist assessment including temporal artery ultrasound (TAU) reduces the risk of LOV and the need for temporal artery biopsy (TAB). Two Consultant Rheumatologists (JSM &amp; JHG), formally trained in TAU, established Scotland’s First Fast Track Referral Pathway for Suspected GCA using TAU on 21.03.17. A third Consultant (SJH), whose formal Vascular ultrasound training occurred later, joined the Service on 10.04.18. We present here our Outcome data and also our experience of this new Service for NHS Fife, the first of it’s kind in Scotland. <h3>Methods:</h3> We prospectively recorded data on all referrals to our Fast Track Service for patients with suspected GCA from 21.03.17 onwards. NHS Fife covers a population of 370,000 and constitutes 6.8% of the Scottish Population (5,425,000). <h3>Results:</h3> Up until 20.11.17 (20 months) we received a total of 142 referrals, representing an average of 7 per month, or around 2 per week. 54 (38%) were deemed to have a very low probability of GCA based on their age, history &amp; CRP and were not seen or scanned. 88 (62%) of referrals underwent Fast Track assessment including TAU (62 F; 26 M); Mean age 71 (range 52-88). Time from referral to assessment was as follows : (25) 28% were seen on the same day; (60) 68% were seen by the next day; (69) 78% were seen within 2 days of referral; (84) 95% were seen within 3 days of referral. 25/88 (28%) patients were diagnosed with GCA. Of these, 14 patients had a positive TAU and did not require TAB. 9 patients had an equivocal or negative TAU and were diagnosed on TAB. Only 1/25 GCA patients experienced LOV (4%). The patient was an 82 year old male diabetic who presented to Ophthalmology with unilateral LOV but no symptoms of GCA and also with a normal CRP (4.1mg/L). However, he had stopped 1mg of prednisolone for PMR 2 weeks prior to developing LOV. TAU was positive, but in view of the atypical nature of his symptoms (“silent GCA”) &amp; normal CRP, he also underwent TAB, which was positive confirming the diagnosis of GCA. I patient had a negative TAU and TAB, but was subsequently diagnosed with LVV on axillary artery US. <h3>Conclusion:</h3> A previous survey of 20 GCA patients diagnosed in Fife over a 2 year period (Jan 2007 - Jan 2009) recorded a 50% rate of LOV. This was largely attributed to delayed referral. We have now successfully introduced Scotland’s First Fast Track Referral Pathway for Suspected GCA using TAU. This has led to a dramatic reduction in Morbidity in terms of LOV (&lt; 5%). <h3>Disclosure of interests:</h3> None declared
Benefits of Stock Epinephrine Likely Misestimated
Authors: Joe K. Gerald
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
PB2213 SPLANCHNIC VEIN THROMBOSIS IN MYELOPROLOFERATIVE NEOPLASMS; A PROSPECTIVE ANALYSIS OF THROMBOSIS OUTCOME
Authors: A. Danaee, D. Yu, F. Chen, D. Patch, D. Tripathi, S. Karkhanis, M. Sekhar
Journal: HemaSphere (2019)

Background: Splanchnic vein thrombosis (SVT) includes extrahepatic portal vein obstruction (EHPVO), Budd‐Chiari syndrome (BCS) and mesenteric vein thrombosis. Myeloproliferative neoplasms (MPN) account for the majority of non‐cirrhotic SVT and are diagnosed in 30% of patients with EHPVO and 40% with BCS. SVT in MPN patients is associated with significant morbidity and mortality. There have been no prospective studies looking at this subset and there is very little in the way of guidance in managing this complex patient group. Aims: MASCOT is a prospective observational longitudinal study of patients with MPN related splanchnic vein thrombosis. The primary end points of the study are to describe morbidity/portal circulation in the patient group over 18‐24months from baseline, assess any changes in end points clinically and radiologically. Methods: 29 patients from two centres were recruited and followed up for 24 months. Radiological primary endpoints, examined changes in initial thrombus, including thrombus extension or recurrence, recanalization in patients without cavernoma and changes in spleen size. Results: The male: female (M:F) was 13:16 with an average age of 48 years (25‐72). The majority of patients had an underlying diagnosis of polycythaemia vera (PV) 13 (45%), followed by essential thrombocythaemia (ET) 9 (31%) and the remaining patients had primary myelofibrosis (PMF), MPN‐unclassified (MPN‐U), post essential thrombocytosis‐MF (PET‐MF). Two patients did not have evidence of MPN on bone marrow histology. 27/29 had the JAK2v617f mutation; 2 had CALR mutation. Summary/Conclusion: In this prospective study of patients we did not observe recurrence or extension of SVT, however a small proportion of patients went on to develop further thrombotic complications whilst on anticoagulation. The study aims to follow patients for duration of five years with repeat imaging and clinical data.
Suspected cluster of Neisseria meningitidis W invasive disease in an elderly care home: do new laboratory methods aid public health action? United Kingdom, 2015
Authors: Jonathan Lawler, Jay Lucidarme, Sydel Parikh, Lorna Smith, Helen Campbell, Ray Borrow, Steve Gray, Kirsty Foster, Shamez Ladhani
Journal: Eurosurveillance (2019)

In 2015, a suspected cluster of two invasive meningococcal disease (IMD) cases of serogroup W Neisseria meningitidis (MenW) occurred in elderly care home residents in England over 7 months; case investigations followed United Kingdom guidance. An incident control team reviewed epidemiological information. Phenotyping of case specimens informed public health action, including vaccination and throat swabs to assess carriage. Whole genome sequencing (WGS) was conducted on case and carrier isolates. Conventional phenotyping did not exclude a microbiological link between cases (case 1 W:2a:P1.5,2 and case 2 W:2a:NT). After the second case, 33/40 residents and 13/32 staff were vaccinated and 19/40 residents and 13/32 staff submitted throat swabs. Two MenW carriers and two MenC carriers were detected. WGS showed that MenW case and carrier isolates were closely related and possibly constituted a locally circulating strain. Meningococcal carriage, transmission dynamics and influence of care settings on IMD in older adults are poorly understood. WGS analyses performed following public health action helped to confirm the close relatedness of the case and circulating isolates despite phenotypic differences and supported actions taken. WGS was not sufficiently timely to guide public health practice.
AB1089 CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS IN NORTH-WESTERN PART OF TURKEY: ANALYSIS OF 139 PATIENTS
Authors: Emel Gönüllü, Didar Şenocak, İlhan Yıldırım, Yunus Emre özer, ünal Erkorkmaz
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Familial Mediterranean fever (FMF) is known the most common monogenic autoinflammatory disease. Its prevalence is reported high from the eastern Mediterranean areas (1) The disease is characterized by episodes of fever, serositis, arthritis,renal complications and other different clinical manifestations (2) <h3>Objectives</h3> Here, we aimed to present our data of our 139 FMF patients for demonstrating the demographic and clinical features of the study group,from North-western part of Turkey. <h3>Methods</h3> A total of 139 FMF patients who were diagnosed and treated in the department of Internal medicine/Rheumatology, Sakarya University (North-western area of Turkey) were included in the study and the demographic and clinical characteristics of the patients were examined. <h3>Results</h3> The mean age of the patients was 39.02 ± 11.3. Male gender was 42 (30.2%) and female gender was 97 (69.8%).107 (77%) of patients had fever and 32 (23%) had no history of fever. 127 (91.4%) patients complained about peritonitis, 27 (%19.4) patients had pleuritic pain, 19 (13.7%) patients had erysipelas like erythema and 53 (38.1%) patients had arthritis attack. 34 (24.5%) patients also had sacroiliitis. The ratio of resistance of treatment response to colchicine drugs that can be available in Turkey (Colchicum dispert<sup>®</sup>), 6 (4.3%) was determined. Interestingly these patients responded to the colchicine drugs available from some other countries from Europe (as Colchicine-opocalcium<sup>®</sup> and Colchicina-lirca<sup>®</sup>) None of our patients needed anti-IL1 therapies. The rate of amyloidosis was 5 (3.6%). <h3>Conclusion</h3> FMF is a disease with high morbidity and mortality, 95.7% of the patients in our region have response to colchicine drugs which is available in our country. The remaining patients have also response to colchicine available from some other countries. None of our patients had anti-IL1 therapies. <h3>References</h3> [1] özen S, Batu ED, Demir S. Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management. Front Immunol. 2017 23;8:253. [2] Alghamdi M. Familial Mediterranean fever, review of the literatureClin Rheumatol. 2017;36:1707-1713. <h3>Disclosure of Interests</h3> None declared
Abstract 16385: Additional Linear Ablation After Circumferential Pulmonary Vein Isolation Does Not Reduce Clinical Recurrence in Patients With Paroxysmal Atrial Fibrillation: Prospective Randomized Study
Authors: Tae-Hoon Kim, Jumbeom Park, Jin-Kyu Park, Ki-Woon Kang, Nam Kyun Kim, Jae-Sun Uhm, Jong-Youn Kim, Boyoung Joung, Moon-Hyoung Lee, Hui-Nam Pak
Journal: Circulation (2013)

Background & objectives: Circumferential pulmonary vein isolation(CPVI) has been considered as the cornerstone forradiofrequency catheter ablation (RFCA) of paroxysmal Atrial fibrillation(PAF). How...
Abstract 15481: Regional Myocardial Systolic Function Using Transmural Myocardial Strain Profile Predicts Postoperative Left Ventricular Systolic Dysfunction in Chronic Aortic Regurgitation
Authors: Akihiro Kaneko, Hidekazu Tanaka, Tetsuari Onishi, Takayuki Tsuji, Kouhei Yamawaki, Keiko Ryo, Alaa M Omar, Kazuhiro Tatsumi, Kensuke Matsumoto, Hiroya Kawai, Ken-ichi Hirata
Journal: Circulation (2010)

Background: We have reported that preoperative peak systolic left ventricular (LV) strain rate predicts postoperative LV systolic dysfunction in chronic aortic regurgitation (AR). However, transmur...
Mental health conditions affect one in five people in conflict zones, study finds
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Around one in five people living in an area of conflict has a mental health condition, according to a major new study.1

Researchers conducted a systematic review and meta analysis of 129 studies published between January 1980 and August 2017 which included data from 39 countries.

The study, published in the Lancet , reported a 22% prevalence (95% uncertainty interval (UI) 18.8 to 25.7) of depression, anxiety, post-traumatic stress disorder, bipolar disorder, or schizophrenia.

The World Health Organization, which co-authored the research, noted that the prevalence of …
plyranges: a grammar of genomic data transformation
Authors: Stuart Lee, Dianne Cook, Michael Lawrence
Journal: Genome biology (2019)

Bioconductor is a widely used R-based platform for genomics, but its host of complex genomic data structures places a cognitive burden on the user. For most tasks, the GRanges object would suffice, but there are gaps in the API that prevent its general use. By recognizing that the GRanges class follows "tidy" data principles, we create a grammar of genomic data transformation, defining verbs for performing actions on and between genomic interval data and providing a way of performing common data analysis tasks through a coherent interface to existing Bioconductor infrastructure. We implement this grammar as a Bioconductor/R package called plyranges.
Abstract 10: Metabolically Healthy Obesity Over 25 Years in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Race and Sex Differences
Authors: Sarah M Camhi, Aviva Must, Philimon N Gona, Arlene Hankinson, Andrew Odegaard, Jared Reis, Erica P Gunderson, David R Jacobs, Mercedes Carnethon
Journal: Circulation (2017)

Background: Obesity is heterogeneous condition with phenotypic variation. Metabolically healthy obese (MHO) may represent an unstable phenotype which changes over time. MHO duration, or the length of time in MHO, is not well characterized. The purpose is to quantify MHO duration over 25 years and explore possible race/sex differences. Methods: Young adults (baseline ages 18-30 yrs) from CARDIA were included if they were non-obese at baseline, developed obesity (BMI ≥30kg/m 2 ) at any follow-up exam (yrs 7, 10, 15, 20 and 25), and had complete data for metabolic status, age, race and sex (n=702). MHO was defined as obese (BMI ≥30 kg/m 2 ) and having either 0 or 1 risk factor of the following: ≥SBP/DBP 130/85 mmHg; glucose ≥100 mg/dL; triglycerides (≥150 mg/dL); and HDL-C (men &lt;40, women &lt;50 mg/dL). Obese individuals with ≥2 risk factors were classified as metabolically unhealthy obese (MUO). MHO duration (yrs) and obesity duration (yrs) were estimated for subsequent time-points; and a duration sum was calculated for the follow-up period. For two time-points in which a person remained MHO and obese, a duration for that period was assigned. If they transitioned to MUO or non-obese, then the midpoint of the time period was estimated as MHO duration (yrs). MHO duration was also expressed as the percentage (%) of the total obesity duration. Multivariable adjusted ANCOVA was used to compare MHO duration (%) between race and sex groups (black men, white men, black women and white women), adjusting for baseline age, baseline BMI status (normal weight or overweight). Results: The eligible CARDIA sample was 55% black, 71% women and had a mean (± SD) baseline age of 25.0 ± 3.7 yrs. Duration of obesity was 12.3 ± 6.8 yrs, MHO duration (yrs) was 6.2 ± 5.4 yrs (range: 0 years to 19 yrs), and MHO duration (%) was 51.9 ± 34.8%. After adjusting for age and baseline BMI, MHO duration (%, mean ± SE) was significantly higher in women compared to men within race (black women n=292: 56.3 ± 2.0% vs. black men n=91: 43.3 ± 3.6%, p=0.001; white women n=206: 56.1 ± 2.4% vs. white men n=113: 39.7 ± 3.2%, p &lt;0.0001). No significant differences were found between race groups within gender (black men vs. white men or black women vs. white women). Conclusion: MHO status is a transient phenotype accounting for only approximately half of obesity duration. Women have longer MHO duration compared to men, but differences by race were not apparent. Future research is needed to explore possible modifiable predictors and/or determinants of longer MHO duration in order to maintain a healthy cardiometabolic phenotype, even in the presence of obesity.
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Authors: Javier Ampuero, Raluca Pais, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, Carmelo García-Monzón, Jerome Boursier, Eduardo Vilar, Salvatore Petta, Ming-Hua Zheng, Desamparados Escudero, Jose Luis Calleja, Patricia Aspichueta, Moisés Diago, Jose Miguel Rosales, Joan Caballería, Judith Gómez-Camarero, Oreste Lo Iacono, Salvador Benlloch, Agustín Albillos, Juan Turnes, Jesus M. Banales, Vlad Ratziu, Manuel Romero-Gómez, Salvador Agustin, Francisco Jorquera, Ruben Frances, Javier Garcia-Samaniego, Javier Salmeron, Conrado Fernandez-Rodriguez, Pamela Estevez, Raul Andrade, German Soriano, Miguel Fernandez-Bermejo, María Teresa Arias Loste, Rebeca Sigüenza, Aurora Giannetti, Elvira del Pozo Maroto
Journal: Clinical Gastroenterology and Hepatology (2019)
PF288 POPULATION PHARMACOKINETIC (POPPK) AND CONCENTRATION‐QTC ANALYSIS OF QUIZARTINIB IN PATIENTS (PTS) WITH FLT3‐ITD–POSITIVE RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
Authors: D. Kang, E. Ludwig, D. Jaworowicz, H. Huang, J. Fiedler‐Kelly, J. Cortes, S. Ganguly, S. Khaled, A. Krämer, M. Levis, G. Martinelli, A. Perl, N. Russell, M. Abutarif, Y. Choi, K. Kobayashi, J. Mendell, O. Yin
Journal: HemaSphere (2019)

Background: Quizartinib is a highly potent and selective FLT3 inhibitor with robust clinical activity in pts with R/R FLT3 ‐ITD AML. Aims: This analysis was conducted to evaluate the PopPK with quizartinib in a pooled analysis of 7 trials and to evaluate the relationship of quizartinib concentration to QTc in patients from the phase 3 QuANTUM‐R (AC220–007) study. Methods: The PopPK analysis included data from 585 participants enrolled in 5 phase 1 studies, 1 phase 2 study (2689‐CL‐2004), and 1 phase 3 study (QuANTUM‐R). Quizartinib was given as single or multiple doses of 20, 30, 60, and 90 mg (17.7, 26.5, 53, 79.5 mg free base). In QuANTUM‐R, the starting dose was 30 mg/day, increased to 60 mg/day after 2 weeks if QTcF was &lt;450 ms. Patients receiving a concurrent strong CYP3A inhibitor initiated quizartinib at 20 mg/day, with an increase to 30 mg/day if QTcF was &lt;450 ms. Concentration‐QTc analysis included only QuANTUM‐R pts (n = 226). Nonlinear mixed‐effects modeling was performed using observed quizartinib concentrations and time‐matched triplicate ECG measurements. Results: Only strong CYP3A inhibitor use produced a meaningful effect on quizartinib overall exposure (AUC)—an approximately 62% increase. Participant status (AML pts vs healthy participants), albumin level, and body surface area were statistically significant factors, but their effects on quizartinib AUC were &lt;20%. QTcF increased in a concentration‐dependent manner, and the predicted mean increase at the maximum concentration of 60 mg was 21.1 ms (90% CI, 18.3–23.6 ms). Hypokalemia (serum potassium &lt;3.5 mmol/L) was a statistically significant covariate affecting baseline QTcF, but no differences in QTcF increase would be expected at the same quizartinib concentration between patients with and those without hypokalemia. Summary/Conclusion: Strong CYP3A inhibitor use was the only clinically meaningful factor affecting quizartinib PK exposure. QTcF showed an exposure‐dependent increase with respect to quizartinib concentration; but no significant factors, including sex and age, were identified affecting the concentration‐QTc relationship. Results support clinical recommendation of dose reduction in pts receiving strong CYP3A inhibitors because quizartinib exposure is increased significantly in the presence of such agents.